Roth Capital lowered the firm’s price target on Globus Medical (GMED) to $105 from $115 and keeps a Buy rating on the shares. The company reported a weaker-than-expected Q1, with net sales missing consensus, as results were impacted by softer enabling tech sales, integration-related supply chain issues, and timing of international distributor orders, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical price target lowered to $80 from $100 at Piper Sandler
- Globus Medical price target lowered to $77 from $88 at BTIG
- Globus Medical Faces Challenges: Hold Rating Amid Revenue Miss and Cautious Outlook
- Cautious Hold Rating on Globus Medical Amid Supply Chain Challenges and Nevro Acquisition Uncertainty
- Globus Medical Reports Q1 2025 Financial Results